CHEN Rong. Interpretation on the 2023 Chinese Menopause Symptom Management and Menopausal Hormone Therapy Guidelines[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(3): 514-519. doi: 10.12290/xhyxzz.2023-0190
Citation:
CHEN Rong. Interpretation on the 2023 Chinese Menopause Symptom Management and Menopausal Hormone Therapy Guidelines[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(3): 514-519. doi: 10.12290/xhyxzz.2023-0190
CHEN Rong. Interpretation on the 2023 Chinese Menopause Symptom Management and Menopausal Hormone Therapy Guidelines[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(3): 514-519. doi: 10.12290/xhyxzz.2023-0190
Citation:
CHEN Rong. Interpretation on the 2023 Chinese Menopause Symptom Management and Menopausal Hormone Therapy Guidelines[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(3): 514-519. doi: 10.12290/xhyxzz.2023-0190
Gynecological Endocrinology and Reproductive Center, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China
Funds:
National High Level Hospital Clinical Research Funding2022-PUMCH-B-123
The essence of menopause is ovarian failure, which has a significant impact on women's health. The goal of menopausal management is to relieve menopause-related symptoms, and hopefully, prevent chronic diseases in old age. Based on comprehensive lifestyle management, various health care measures including menopausal hormone therapy have been carried out under the guidance of professional medical practitioners so as to improve and enhance the quality of life of middle-aged and elderly women. The 2023 Chinese Menopause Symptom Management and Menopausal Hormone Therapy Guidelines was officially published in January 2023, and this article interprets the core points of the guidelines, especially the main updates, in order to better guide clinical practice.
Bai R, Liu Y, Zhang L, et al. Projections of future life expectancy in China up to 2035: a modelling study[J]. Lance Public Health, 2023: S2468-2667(22)00338-3.
Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: individual articipant meta-analysis of the worldwide epidemiological evidence[J]. Lancet, 2019, 394: 1159-1168. doi: 10.1016/S0140-6736(19)31709-X
[5]
Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of breast cancer: nested case-control studies using the QResearch and CPRD databases[J]. BMJ, 2020, 371: m3873. http://www.xueshufan.com/publication/3097702496
[6]
Chlebowski RT, Anderson GL, Aragaki AK, et al. Association of Menopausal Hormone Therapy with Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women's Health Initiative Randomized Clinical Trials[J]. JAMA, 2020, 324: 369-380. doi: 10.1001/jama.2020.9482
[7]
The 2022 hormone therapy position statement of The North American Menopause Society[J]. Menopause, 2022, 29: 767-794.
[8]
Academic Committee of the Korean Society of Menopause, Lee SR, Cho MK, et al. The 2020 Menopausal Hormone Therapy Guidelines[J]. J Menopausal Med, 2020, 26: 69-98. doi: 10.6118/jmm.20000
[9]
Harlow SD, Gass M, Hall JE, et al. STRAW+10 Collaborative Group. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging[J]. Menopause, 2012, 19: 387-395. doi: 10.1097/gme.0b013e31824d8f40
[10]
Li J, Luo M, Tang R, et al. Vasomotor symptoms in aging Chinese women: findings from a prospective cohort study[J]. Climacteric, 2020, 23: 46-52. doi: 10.1080/13697137.2019.1628734
[11]
Saccardi C, Spagnol G, Bonaldo G, et al. New Light on Endometrial Thickness as a Risk Factor of Cancer: What Do Clinicians Need to Know?[J]. Cancer Manag Res, 2022, 14: 1331-1340. doi: 10.2147/CMAR.S294074